Summary
This Form 8-K/A filing from Vertex Pharmaceuticals Incorporated (VRTX) on May 11, 2009, serves as an amendment to a previous report filed on March 13, 2009, concerning the acquisition of ViroChem Pharma Inc. The primary purpose of this amendment is to provide crucial financial information related to the ViroChem acquisition, which was completed on March 12, 2009. Investors can find the audited condensed financial statements for ViroChem for the years ended December 31, 2008 and 2007, as well as unaudited pro forma condensed combined financial statements for Vertex and ViroChem for the year ended December 31, 2008. These newly filed financial statements are essential for investors to assess the financial impact of the ViroChem acquisition on Vertex Pharmaceuticals. The pro forma statements, in particular, offer a combined view of the merged entities, allowing for a more comprehensive understanding of the company's financial position and performance post-acquisition. The filing adheres to the provision allowing for the submission of these financial details within 75 days of the acquisition date.
Key Highlights
- 1Vertex Pharmaceuticals filed an amended 8-K report on May 11, 2009, to supplement a previous filing concerning the acquisition of ViroChem Pharma Inc.
- 2The amendment was made to include required financial statements related to the acquired business, ViroChem.
- 3Audited condensed financial statements for ViroChem for the years ended December 31, 2008, and 2007, are now provided.
- 4Unaudited pro forma condensed combined financial statements for Vertex and ViroChem as of and for the year ended December 31, 2008, are included.
- 5The acquisition of ViroChem was completed on March 12, 2009.
- 6The filing includes consents from Deloitte & Touche LLP.
- 7The amended report provides investors with a clearer financial picture of the acquired entity and the combined company's pro forma performance.